# Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia

Study · id `cardio:ct-nct04061824` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04061824](<https://clinicaltrials.gov/study/NCT04061824>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04061824

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

## Technical summary

Registry record NCT04061824. Randomized; no masking; primary purpose other. Start 2016-05-24 (actual); primary completion 2018-12-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose other
- Phase: Phase 4
- Enrolled: 150 participants (enrolled count; ClinicalTrials.gov record NCT04061824, source copy `cardio:ctgov-nct04061824-2019-08-21`, retrieved 2026-10-26)
- Started: 2016-05-24 (actual) (ClinicalTrials.gov record NCT04061824, source copy `cardio:ctgov-nct04061824-2019-08-21`, retrieved 2026-10-26)
- Primary completion: 2018-12-20 (actual) (ClinicalTrials.gov record NCT04061824, source copy `cardio:ctgov-nct04061824-2019-08-21`, retrieved 2026-10-26)
- Completion: 2018-12-20 (actual) (ClinicalTrials.gov record NCT04061824, source copy `cardio:ctgov-nct04061824-2019-08-21`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04061824, source copy `cardio:ctgov-nct04061824-2019-08-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04061824-2019-08-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia
- Condition: Hypertension
- Condition: Dyslipidemias
- Intervention (Drug): Olostar Tab (olmesartan/rosuvastatin FDC(fixed dose combination))
- Intervention (Drug): Two separated drugs(ARB(Angiotensin Ⅱ receptor blocker) and statin)
- Lead sponsor: Yonsei University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Yonsei University (`cardio:org-yonsei-university`)

## Provenance

Content hash: f929eb61f89f58ea91359c6d3b93b9c6586b5d1c7b44b29e471c57e74e94caa4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
